Loading
Recovery became a research subject because children started surviving cancer and someone wrote down what the cure had cost. Sixty years later the damage is well measured, exercise is the only thing proven to change a hard outcome, and the next decade turns on whether anyone funds the trials and the services the evidence already justifies.
Five things had to happen before this field could exist. Cancer had to become curable, which happened in paediatric oncology first. Someone had to say that cure was not the end of the question, which Giulio D'Angio did in 1975 and Fitzhugh Mullan did for adults in 1985. The people it was happening to had to organise, which they did in Albuquerque in 1986 and which produced the definition of survivor that national institutes now use. The cost had to be measured in cohorts large enough to attribute a late effect to a dose, which the Childhood Cancer Survivor Study and its successors did from 1994. And a report had to define what good survivorship care consists of, which the Institute of Medicine did in 2006.
What followed is a more mixed record than that sequence suggests. The instrument the 2006 report invented, the survivorship care plan, was mandated into accreditation standards and then failed its randomised trials; the 2018 systematic review's verdict is that existing research provides little evidence that such plans improve health outcomes and health care delivery. The national programme England ran from 2007 produced a sensible minimum bundle and measured that only a quarter of people were offered the least demanding part of it. Meanwhile de-escalation worked: late mortality after childhood cancer fell because treatment was made gentler on the strength of cohort evidence, which is the field's clearest success and is a success in prevention rather than in repair.
The decisive result arrived in 2025. The CHALLENGE trial randomised 889 people with resected colon cancer after adjuvant chemotherapy to a three-year coached exercise programme or to health-education materials, and found longer disease-free survival (hazard ratio 0.72) and longer overall survival (hazard ratio for death 0.63), with eight-year overall survival of 90.3 against 83.2 per cent. That is the first randomised proof that something done after treatment changes whether the cancer comes back, and it is the benchmark every rejuvenation claim should now be measured against.
The frontier runs in the opposite direction. Cancer treatment measurably accelerates epigenetic clocks, senescence markers and physiological frailty; nothing has been shown to reverse any of it; and a retail industry selling stem cell infusions, exosomes, unlicensed peptides, intravenous NAD+ and compounded hormone pellets to people who have just finished treatment has grown up in the gap between the measurement and the evidence. The honest statement of the field's position is that the acceleration is real, nothing sold on the strength of it has been shown to reverse it, and the distance between those two sentences is where the research belongs.
What the next decade turns on is unusually clear and unusually unglamorous: endpoints the field has not agreed, registries that do not record late effects, services that are recommended and not commissioned, and follow-up nobody owns. None of it needs a discovery.
Combination chemotherapy and radiotherapy made childhood leukaemia and several childhood solid tumours curable within about fifteen years, and the first cured children reached adulthood. Giulio D'Angio's 1975 paper in Cancer, "Pediatric cancer in perspective: cure is not enough", named the consequence: a field that measures five-year survival will not see a thirty-year-old with heart failure, a second cancer and no fertility, because none of those is in its denominator. The evidence for the next twenty years was single-hospital case series, enough to raise an alarm and not enough to quantify one.
Fitzhugh Mullan's three-page essay in the New England Journal of Medicine divided survival into acute, extended and permanent seasons and asked medicine to map the middle ground. Twenty-three people founded the National Coalition for Cancer Survivorship in Albuquerque in 1986 to replace the words "cancer victim" with "cancer survivor"; their definition, a survivor from diagnosis for the balance of life, is the National Cancer Institute's definition today. In 1996, after reading the coalition's Imperatives for Quality Cancer Care, the Institute's director established the Office of Cancer Survivorship, which is still the body that counts survivors and funds research into what happens to them.
The Childhood Cancer Survivor Study assembled 20,276 eligible five-year survivors from 25 institutions with treatment records abstracted for 98 per cent of participants, which is what lets a late effect be tied to a cumulative dose rather than to a diagnosis. Its 2006 analysis found 62.3 per cent of adult survivors with a chronic health condition and 27.5 per cent with a severe or life-threatening one. The St Jude Lifetime Cohort examined survivors clinically in 2013 and found more than questionnaires had shown. The British and European cohorts and the International Guideline Harmonization Group followed, and risk-based follow-up guidelines were written from the results. Treatment was then de-escalated on the strength of them, and late mortality after childhood cancer fell: the field's clearest success, and a success in prevention rather than repair.
The Institute of Medicine's "Lost in Transition" defined survivorship care as prevention, surveillance, intervention and coordination, made ten recommendations, and invented the survivorship care plan, which became an accreditation standard. Then it was tested. A randomised trial in breast cancer in 2011 found no difference; a 2018 systematic review of thirteen randomised and eleven non-randomised studies concluded that existing research provides little evidence that such plans improve health outcomes and health care delivery. England's National Cancer Survivorship Initiative ran from 2007, defined a Recovery Package, and measured that 24 per cent of people were offered a written assessment and care plan. The lesson the field took, and is still acting on, is that a document is not a service.
The American College of Sports Medicine roundtable stated a dose specific enough to prescribe: moderate aerobic exercise at least three times a week for at least thirty minutes over eight to twelve weeks, plus resistance training twice a week. A meta-analysis of 113 studies and 11,525 participants put exercise ahead of psychological therapy and far ahead of drugs for fatigue, with the pharmaceutical effect not reaching significance. Then CHALLENGE randomised 889 people after colon cancer chemotherapy and found longer disease-free and overall survival with a three-year coached programme. For the first time something done after treatment changed whether the cancer came back, and the honest cost was recorded too: more musculoskeletal adverse events in the exercise group.
Epigenetic clocks, p16INK4a, telomere length and physiological frailty each showed that cancer treatment ages people faster than time does, with the childhood cohorts supplying most of the numbers. None of those measures is a validated clinical test, none is used to make a treatment decision, and no trial has shown that moving one changes anything. In the same decade a market grew in the gap: stem cell infusions, exosomes, unlicensed peptides, intravenous NAD+, ozone and compounded hormone pellets, sold to people who have just finished treatment, several of them the subject of regulatory warnings. This front grades each of them rather than omitting them, because a reader who finds nothing here finds the seller's page instead.
The nearest available gains need no discovery. A rehabilitation prescription written at the end of treatment and funded like a drug; psychological therapy with a referral route rather than a leaflet; a treatment-exposure record a machine can read, so that a survivor or a general practitioner can be told what surveillance is due this year; accountability for the checks that do not happen. The trials being run now are of exactly these: a stepped-care late-effects service after allogeneic transplant, an occupational-therapy return-to-work programme with a cost-effectiveness analysis attached, a virtual exercise-based rehabilitation programme for persistent chemotherapy nerve damage. The constraint is commissioning rather than evidence.
Several of the questions here cannot be answered until the measurements agree. Core outcome sets for the main late effects would let the next systematic review pool rather than narrate, and would end prevalence ranges like the 0 to 84 per cent reported for kidney impairment after childhood cancer. A function endpoint paired with a biological-age secondary would let a trial say whether the clock tracks the thing that matters; PROFFi, testing fisetin with and without exercise against frailty in breast cancer survivors, has that shape. Registry-based randomisation is the only plausible route to asking whether any survivorship screening programme saves lives. And a platform trial would let survivorship interventions share a control arm instead of each raising its own.
Almost everything on this front today is prevention, substitution or surveillance. The things that would count as rejuvenation are restoring an immune repertoire rather than revaccinating around a narrowed one, regenerating a thymus in an adult, restoring processing speed rather than teaching strategies to work around its loss, reversing fibrosis that has set in a radiotherapy field, and growing the salivary and dental tissue that head and neck radiotherapy destroys. None has a human trial in cancer survivors. They are listed here as the honest contents of the word rejuvenation, and as the measure of how far the field is from it: everything currently sold under that word has less evidence than a supervised exercise programme.
Four constraints bind, and none of them is biological. Nothing here is a product, so nothing here has a sponsor to fund its trial or lobby for its payment code. Registries count diagnoses and deaths and not what treatment left behind, so the scale that would justify a budget has never been produced. Follow-up belongs to an oncology service that discharges and a primary care service that was never sent the exposure history, so it belongs to nobody. And the field has not agreed what to measure, so studies cannot be pooled and trials fail for want of an endpoint. Every one of those is fixable with money and agreement rather than with a discovery, which is either the most encouraging or the most frustrating sentence on this roadmap.
Every era's records, trial outcomes and papers, and every watch item, as JSON.
Probability ranges are named estimates that the claim is borne out on roughly a five-year horizon. They are meant to be argued with: propose a revision with your name and reasoning via a pull request to src/data/confidence.ts.
Readouts, decisions and registry completion dates ahead. Each date is quoted from its source, not inferred; a missing date means no source states one.
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Shares Mesenchymal stromal cells for tissue damage, Stem cell clinics and stem cell tourism, Telomere length after treatment, Skin during and after radiotherapy: dressings, steroids and what lasts.
Shares Nobody owns the follow-up once the oncology clinic lets go, Late deaths after childhood cancer, what causes them, and the proof that gentler treatment worked, St Jude Lifetime Cohort Study (SJLIFE), International Guideline Harmonization Group for late effects of childhood cancer.
Shares No treatment restores the thinking that cancer treatment takes, Agree what to measure, so the next systematic review can pool rather than narrate, The field cannot pool its own studies, because it has not agreed what to measure, Cognitive behavioural therapy for insomnia (CBT-I).
Shares Survivorship care plans generated automatically from the treatment record, Make the treatment exposure record machine-readable, so surveillance can be computed, Nobody owns the follow-up once the oncology clinic lets go, PanCareSurFup and the European survivor cohorts.
Shares Write a rehabilitation prescription at the end of treatment, and fund it like a drug, Rehabilitation is recommended everywhere and commissioned almost nowhere, CHALLENGE (CCTG CO.21), Structured exercise programmes after curative treatment.
Shares AlloCare: a stepped-care late-effects service after allogeneic transplant, Lost in Transition: the 2006 report that defined survivorship care, and the care plan it invented, Make the treatment exposure record machine-readable, so surveillance can be computed, Nobody owns the follow-up once the oncology clinic lets go.
Shares No treatment restores the thinking that cancer treatment takes, St Jude Lifetime Cohort Study (SJLIFE), International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines.
Shares Agree what to measure, so the next systematic review can pool rather than narrate, The field cannot pool its own studies, because it has not agreed what to measure, St Jude Lifetime Cohort Study (SJLIFE), International Guideline Harmonization Group for late effects of childhood cancer.